Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Indirect comparison between immune checkpoint inhibitors approved in second line.
| Drug | Phase | Patients | ORR (%) | mOS |
|---|---|---|---|---|
| Pembrolizumab | III | 542 | 21.1 | 10.1 months |
| Atezolizumab* | III | 931 | 13.4 | 11.1 months |
| Atezolizumab* | II | 316 | 15 | 7.9 months |
| Nivolumab | II | 265 | 20.7 | 8.7 months |
| Avelumab | I | 249 | 17 | 6.5 months |
| Durvalumab* | I/II | 182 | 17.8 | 18.2 months |
FDA indication for second line treatment in mUC was withdrawn in 2021.
mOS, median overall survival; ORR, overall response rate.
